About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Rheumatoid Arthritis Clinical Trials in Houston | 3,412 Studies | Clareo Health

Clinical Trials Rheumatoid ArthritisHouston

Rheumatoid Arthritis Clinical Trials in Houston

Find 3,412 clinical trials for rheumatoid arthritis near Houston, Texas. Connect with research centers in your area.

All Rheumatoid Arthritis trials nationwide All trials in Houston

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3181-3200 of 3,412 trials

COMPLETEDPhase 2< 1 mile

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01281631

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS.

Amyotrophic Lateral Sclerosis

Neuraltus Pharmaceuticals, Inc.136 participantsStarted Feb 2011

Scottsdale, Arizona, United States • Irvine, California, United States • Los Angeles, California, United States +14 more locations

COMPLETEDPhase 3< 1 mile

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

NCT00542685

This study will evaluate the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder.

Generalized Anxiety Disorder

Pfizer551 participantsStarted Oct 2007

Beverly Hills, California, United States • Encino, California, United States • National City, California, United States +40 more locations

Rheumatoid Arthritis Trials in Other Cities

New York Los Angeles Chicago Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TERMINATEDPhase 3< 1 mile

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

NCT00658372

This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages 18 to 65, with generalized anxiety disorder.

Generalized Anxiety Disorder

Pfizer360 participantsStarted May 2008

Arcadia, California, United States • Costa Mesa, California, United States • Escondido, California, United States +30 more locations

COMPLETEDPhase 3< 1 mile

An Implantable Spinal Cord Stimulation Pain Management System

NCT00205855

There are many treatment options available for the management of chronic pain . Some include, but are not limited to, over-the-counter medications, Non-Steroidal Anti-Inflammatory Drugs, Physical Therapy, Transcutaneous Electrical Nerve Stimulation (TENS) and nerve blocks. Historically, the mainstay of pain treatment has been pharmacotherapy. However, pharmacotherapy has varying degrees of effectiveness and is often associated with undesirable side effects. Although many patients are successfully treated, for those who fail some of these more conservative therapies the remaining option is limited to spinal cord stimulation (SCS), proven to be an effective therapy to more than half of those failing conservative treatments . Over 50% of those who have failed these more conservative methods of pain management, can now, under the guidance of a clinician utilizing SCS, have their pain levels successfully managed. SCS is a less invasive therapy that is a reversible treatment with greater long-term benefits than more permanent, radical approaches and one that deserves greater consideration in the management of chronic, intractable pain.

Chronic PainPain, IntractablePain+2 more

Boston Scientific Corporation65 participantsStarted Feb 2003

Huntsville, Alabama, United States • Los Angeles, California, United States • San Francisco, California, United States +6 more locations

TERMINATEDNA< 1 mile

Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

NCT00720837

The goal of this clinical research study is to learn about a new therapy device called the Visualase® Thermal Therapy System (a device that uses a laser to kill tumor cells and is guided using magnetic resonance thermal imaging \[MRTI\]). The Visualase® Thermal Therapy System is used to treat metastatic brain tumors. Researchers want to find out if it is possible to use this new device in patients with metastatic brain tumor(s), each measuring 3 centimeters (cm) or smaller. The safety of the device will also be studied.

M.D. Anderson Cancer Center6 participantsStarted Jul 2008

Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

NCT00014144

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have advanced cancer of the urinary tract.

Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer

SWOG Cancer Research Network31 participantsStarted Feb 2001

Birmingham, Alabama, United States • Mobile, Alabama, United States • Phoenix, Arizona, United States +92 more locations

TERMINATEDPhase 3< 1 mile

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236

This trial is a longterm follow up of a phase III study of inhaled cyclosporine for the prevention of chronic rejection in lung transplant recipients.

Lung Transplant

APT Pharmaceuticals, Inc.17 participantsStarted Dec 2009

Los Angeles, California, United States • San Francisco, California, United States • Stanford, California, United States +13 more locations

COMPLETEDPhase 3< 1 mile

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

NCT00003293

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether SU-101 is more effective than procarbazine in treating patients with glioblastoma multiforme. PURPOSE: Randomized phase III trial to compare the effectiveness of SU-101 with that of procarbazine in treating patients with glioblastoma multiforme that has recurred.

Brain and Central Nervous System Tumors

PfizerStarted Feb 1998

Phoenix, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +32 more locations

TERMINATEDNA< 1 mile

Effectiveness Study of the BOA(R)-Constricting IV Band

NCT01104103

The purpose of this study is to determine whether the BOA(R)-Constricting IV Band is superior to standard methods for starting an IV.

Catheterization, Peripheral

The University of Texas Health Science Center, Houston467 participantsStarted Mar 2010

Houston, Texas, United States • Houston, Texas, United States

COMPLETEDPhase 3< 1 mile

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274

This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.

Graft Rejection

Novartis Pharmaceuticals721 participantsStarted Jan 2006

Los Angeles, California, United States • San Francisco, California, United States • Stanford, California, United States +61 more locations

COMPLETEDNA47 miles

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

NCT00000883

The purpose of this study is to see if there are any changes in sugar and fat levels in the blood when patients take anti-HIV therapy for many years. Another goal is to test memory and mental concentrations to determine if anti-HIV drugs protect the brain from damage caused by HIV. (The purpose of this study has been changed from the original version.) HIV-infected patients with low CD4 cell counts are at risk for getting opportunistic (AIDS-related) infections. CD4 cells are cells of the immune system that help fight infection. Anti-HIV therapy may increase CD4 counts, which may lead to a decrease in AIDS-related infections. Problems that anti-HIV therapy is associated with include metabolic problems, neurologic problems, abnormal opportunistic infections, and cancer. Patients in ACTG 362 have been exposed to anti-HIV therapy longer than any other large group in the ACTG. These patients appear to benefit from their therapy, but also suffer problems from it. Observation of these patients should provide more information about long-term anti-HIV treatment and may detect unexpected problems. (This study as been changed. More information about the reasons for conducting this study has been added.)

Mycobacterium Avium-intracellulare InfectionHIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)636 participantsStarted Oct 1997

Birmingham, Alabama, United States • Los Angeles, California, United States • Menlo Park, California, United States +48 more locations

TERMINATEDPhase 350 miles

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

NCT00658008

This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder.

Generalized Anxiety Disorder

Pfizer501 participantsStarted Apr 2008

Litchfield Park, Arizona, United States • Costa Mesa, California, United States • Pasadena, California, United States +49 more locations

COMPLETEDPhase 3183 miles

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

NCT00366834

This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.

VomitingNauseaNausea and Vomiting, Chemotherapy-Induced

GlaxoSmithKline1,840 participantsStarted Jul 2006

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Glendale, Arizona, United States +220 more locations

COMPLETEDPhase 4214 miles

Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

NCT00337493

This study will determine which, if any, allelic variants of mycophenolic acid (MPA) metabolizing enzymes, drug transporters and drug targets are associated with the observed variation in pharmacokinetic and pharmacodynamic outcomes observed with CellCept usage. Patients participating in study ML17225 will be eligible for this pharmacogenetic investigation, and will have one additional blood sample taken during the study. The anticipated time on study treatment in study ML17225 is 1-2 years, and the target sample size is 500+ individuals.

Kidney Transplantation

Hoffmann-La Roche155 participantsStarted Dec 2005

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +17 more locations

TERMINATEDPhase 2225 miles

Belatacept in Liver Transplant Recipients

NCT00555321

The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant

Immunosuppression in Solid Organ Transplant

Bristol-Myers Squibb260 participantsStarted Jan 2008

Phoenix, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +39 more locations

TERMINATEDPhase 3225 miles

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187

This was a pivotal trial to determine whether LX201 reduces the likelihood of a graft rejection episode following corneal transplantation in patients at high immunological risk for rejection.

Corneal DiseasesCornea Transplant

Lux Biosciences, Inc.368 participantsStarted Apr 2007

Phoenix, Arizona, United States • Loma Linda, California, United States • Los Angeles, California, United States +27 more locations

TERMINATEDPhase 4225 miles

Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)

NCT00796705

Rheumatoid Arthritis (RA) is a systemic inflammatory autoimmune disorder that leads to inflammation and progressive joint damage affecting 2.5 million people in the United States. The primary purpose of this study is to determine the effectiveness of switching to an alternative Tumor Necrosis Factor (TNF) alpha inhibitor in comparison to continuing treatment with an existing TNF-alpha inhibitor in adults suffering from RA in a setting of inadequate clinical response to etanercept or adalimumab.

Rheumatoid Arthritis

National Institute of Allergy and Infectious Diseases (NIAID)13 participantsStarted Nov 2008

Birmingham, Alabama, United States • Palo Alto, California, United States • New Haven, Connecticut, United States +13 more locations

COMPLETEDNA318 miles

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

NCT00000666

To evaluate pyrimethamine as a prophylactic agent against toxoplasmic encephalitis in individuals who are coinfected with HIV and latent Toxoplasma gondii. Toxoplasmic encephalitis is a major cause of illness and death in AIDS patients. Standard treatment for toxoplasmic encephalitis is to combine pyrimethamine and sulfadiazine. Continuous treatment is necessary to prevent recurrence of the disease, but constant use of pyrimethamine/sulfadiazine is associated with toxicity. Clindamycin has been shown to be effective in treatment of toxoplasmic encephalitis in animal studies. This study evaluates pyrimethamine as a preventive treatment against toxoplasmic encephalitis (per 3/26/91 amendment, clindamycin arm was discontinued).

Toxoplasmosis, CerebralHIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)600 participants

San Francisco, California, United States • Denver, Colorado, United States • New Haven, Connecticut, United States +13 more locations

COMPLETEDPhase 2354 miles

Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age

NCT00488345

To determine the pharmacokinetic profile and to evaluate the safety and tolerability of ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious infections; complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), or community-acquired pneumonia (CAP).

Bacterial InfectionsIntra-Abdominal InfectionPneumonia, Bacterial+2 more

Wyeth is now a wholly owned subsidiary of Pfizer59 participantsStarted Dec 2007

Long Beach, California, United States • Oakland, California, United States • Orange, California, United States +33 more locations

TERMINATEDPhase 4666 miles

Acute Cough Study In Children

NCT01257542

15 mg dextromethorphan hydrobromide will be better than placebo with respect to reducing the number of coughs over 6 hours and reducing the subjective severity of cough over 6 hours.

Common ColdInfections, Upper Respiratory Tract

Pfizer140 participantsStarted Dec 2010

Pinellas Park, Florida, United States • Indianapolis, Indiana, United States • Gresham, Oregon, United States +1 more locations

PreviousPage 160 of 171Next

Other Conditions in Houston

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia